RPRX — Royalty Pharma · catalysts, narrative & risks

Profile and current snapshot

Royalty Pharma plc (NASDAQ: RPRX) buys biopharmaceutical royalties and funds R&D, holding royalty interests in roughly 35 marketed therapies and 20 development-stage candidates spanning rare disease, oncology, neuroscience, infectious disease, hematology and diabetes [15]. It operates "like both a biopharma company and a venture capital firm" [10]. As of the October 2, 2026 close, the stock traded ~$57.16 [10][14][15].